IkT-001Pro for CML

Improved, Safer Imatinib

Inhibikase developed IkT-001Pro an outgrowth of our efforts to improve the safety of the first FDA-approved Abl kinase inhibitor, imatinib (Gleevec®), which is commonly taken for hematological and gastrointestinal cancers that arise from Abl kinase mutations in bone marrow or Kit kinase mutations in the stomach.

IkT-001Pro has been shown to be as much as 13 times safer than imatinib in non-human primates, blunting the severe gastrointestinal side effects of imatinib therapy for cancer. Removing these gastrointestinal side effects has the potential to double the number of patients that reach complete cytogenetic response in stable-phase chronic myelogenous leukemia (CML).

IkT-001Pro for CML is on an accelerated development pathway for approval through the 505(b)2 approval guidelines.

Back to Top